{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Human+Immunodeficiency+Virus+Infection%28HIV%29%2FAcquired+Immunodeficiency+Syndrome+%28AIDS%29&page=4",
    "query": {
      "condition": "Human Immunodeficiency Virus Infection(HIV)/Acquired Immunodeficiency Syndrome (AIDS)",
      "page": 4
    },
    "page_size": 10
  },
  "pagination": {
    "page": 4,
    "page_size": 10,
    "total_count": 1706,
    "total_pages": 171,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Human+Immunodeficiency+Virus+Infection%28HIV%29%2FAcquired+Immunodeficiency+Syndrome+%28AIDS%29&page=5&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Human+Immunodeficiency+Virus+Infection%28HIV%29%2FAcquired+Immunodeficiency+Syndrome+%28AIDS%29&page=3&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-14T09:45:54.921Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02285114",
      "title": "Study To Evaluate Emtricitabine/Tenofovir Alafenamide (F/TAF) in Human Immunodeficiency Virus 1 (HIV-1) Infected Children and Adolescents Virologically Suppressed on a 2-Nucleoside/Nucleotide Reverse Transcriptase Inhibitor (2-NRTI)-Containing Regimen",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "HIV-1"
      ],
      "interventions": [
        {
          "name": "F/TAF",
          "type": "DRUG"
        },
        {
          "name": "3rd ARV agent",
          "type": "DRUG"
        },
        {
          "name": "Boosted PIs",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Month",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "1 Month to 17 Years"
      },
      "enrollment_count": 41,
      "start_date": "2015-01-20",
      "completion_date": "2024-12-11",
      "has_results": true,
      "last_update_posted_date": "2025-06-27",
      "last_synced_at": "2026-10-14T09:45:54.921Z",
      "location_count": 4,
      "location_summary": "Los Angeles, California • Aurora, Colorado • Philadelphia, Pennsylvania + 1 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02285114"
    },
    {
      "nct_id": "NCT04925752",
      "title": "Pre-Exposure Prophylaxis Study of Lenacapavir in Cisgender Men, Transgender Women, Transgender Men, and Gender Nonbinary People at Risk for HIV Infection",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Pre-Exposure Prophylaxis of HIV Infection"
      ],
      "interventions": [
        {
          "name": "Oral Lenacapavir (LEN)",
          "type": "DRUG"
        },
        {
          "name": "F/TDF",
          "type": "DRUG"
        },
        {
          "name": "Sub-cutaneous (SC) Lenacapavir (LEN)",
          "type": "DRUG"
        },
        {
          "name": "Placebo SC LEN",
          "type": "DRUG"
        },
        {
          "name": "PTM F/TDF",
          "type": "DRUG"
        },
        {
          "name": "PTM Oral LEN",
          "type": "DRUG"
        },
        {
          "name": "F/TAF (for US participants only)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "16 Years and older"
      },
      "enrollment_count": 3292,
      "start_date": "2021-06-28",
      "completion_date": "2028-08",
      "has_results": true,
      "last_update_posted_date": "2026-10-06",
      "last_synced_at": "2026-10-14T09:45:54.921Z",
      "location_count": 60,
      "location_summary": "Birmingham, Alabama • Loma Linda, California • Los Angeles, California + 43 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Loma Linda",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04925752"
    },
    {
      "nct_id": "NCT00891358",
      "title": "Empowerment Intervention for Young Women - Phase I",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "HIV",
        "Empowerment",
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Prevention Empowerment Intervention for Young Women",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "University of North Carolina, Chapel Hill",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": "24 Years",
        "sex": "FEMALE",
        "summary": "16 Years to 24 Years · Female only"
      },
      "enrollment_count": 17,
      "start_date": "2008-11",
      "completion_date": "2013-04",
      "has_results": false,
      "last_update_posted_date": "2017-03-06",
      "last_synced_at": "2026-10-14T09:45:54.921Z",
      "location_count": 3,
      "location_summary": "Tampa, Florida • Chicago, Illinois • Baltimore, Maryland",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00891358"
    },
    {
      "nct_id": "NCT00000684",
      "title": "Continuous High-Dose Intravenous Dextran Sulfate in Human Immunodeficiency Virus-Infected Individuals",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Dextran sulfate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "19 Years and older"
      },
      "enrollment_count": 10,
      "start_date": null,
      "completion_date": "1991-04",
      "has_results": false,
      "last_update_posted_date": "2021-11-03",
      "last_synced_at": "2026-10-14T09:45:54.921Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00000684"
    },
    {
      "nct_id": "NCT05363865",
      "title": "Digital Community to Improve Health in Rural Areas",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "HIV Infections",
        "Hepatitis C Virus Infection"
      ],
      "interventions": [
        {
          "name": "Virtual Community Intervention",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Standard of Care",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "University of Pennsylvania",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 511,
      "start_date": "2023-06-12",
      "completion_date": "2025-08-31",
      "has_results": false,
      "last_update_posted_date": "2026-03-19",
      "last_synced_at": "2026-10-14T09:45:54.921Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05363865"
    },
    {
      "nct_id": "NCT01771107",
      "title": "Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With Stage II-IV HIV-Associated Hodgkin Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "AIDS-Related Hodgkin Lymphoma",
        "Ann Arbor Stage II Hodgkin Lymphoma",
        "Ann Arbor Stage IIA Hodgkin Lymphoma",
        "Ann Arbor Stage IIB Hodgkin Lymphoma",
        "Ann Arbor Stage III Hodgkin Lymphoma",
        "Ann Arbor Stage IIIA Hodgkin Lymphoma",
        "Ann Arbor Stage IIIB Hodgkin Lymphoma",
        "Ann Arbor Stage IV Hodgkin Lymphoma",
        "Ann Arbor Stage IVA Hodgkin Lymphoma",
        "Ann Arbor Stage IVB Hodgkin Lymphoma",
        "Classic Hodgkin Lymphoma",
        "HIV Infection"
      ],
      "interventions": [
        {
          "name": "Brentuximab Vedotin",
          "type": "DRUG"
        },
        {
          "name": "Dacarbazine",
          "type": "DRUG"
        },
        {
          "name": "Doxorubicin Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Pharmacological Study",
          "type": "OTHER"
        },
        {
          "name": "Vinblastine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 41,
      "start_date": "2013-03-08",
      "completion_date": "2024-03-21",
      "has_results": true,
      "last_update_posted_date": "2025-08-15",
      "last_synced_at": "2026-10-14T09:45:54.921Z",
      "location_count": 20,
      "location_summary": "La Jolla, California • Los Angeles, California • Sacramento, California + 10 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01771107"
    },
    {
      "nct_id": "NCT00996970",
      "title": "Immunogenicity of Novel H1N1 Vaccination Among HIV-Infected Compared to HIV-Uninfected Persons",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Influenza",
        "HIV Infections"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Henry M. Jackson Foundation for the Advancement of Military Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 132,
      "start_date": "2009-10",
      "completion_date": "2022-12",
      "has_results": false,
      "last_update_posted_date": "2023-03-22",
      "last_synced_at": "2026-10-14T09:45:54.921Z",
      "location_count": 3,
      "location_summary": "San Diego, California • Bethesda, Maryland • Portsmouth, Virginia",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Bethesda",
          "state": "Maryland"
        },
        {
          "city": "Portsmouth",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00996970"
    },
    {
      "nct_id": "NCT03407105",
      "title": "A Dose-Escalation Study of MDX-010 Administered Monthly as Immunotherapy in Subjects Infected With Human Immunodeficiency Virus (HIV)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Human Immunodeficiency Virus (HIV)"
      ],
      "interventions": [
        {
          "name": "MDX-010",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 24,
      "start_date": "2003-04-21",
      "completion_date": "2006-02-21",
      "has_results": false,
      "last_update_posted_date": "2018-01-23",
      "last_synced_at": "2026-10-14T09:45:54.921Z",
      "location_count": 5,
      "location_summary": "Los Angeles, California • San Francisco, California • Miami, Florida + 2 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03407105"
    },
    {
      "nct_id": "NCT00006441",
      "title": "Effectiveness of Adding Interleukin-2 to Anti-HIV Drugs in Patients Recently Infected With HIV",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Lamivudine/Zidovudine",
          "type": "DRUG"
        },
        {
          "name": "Nelfinavir mesylate",
          "type": "DRUG"
        },
        {
          "name": "Aldesleukin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 398,
      "start_date": "2003-02",
      "completion_date": "2008-10",
      "has_results": false,
      "last_update_posted_date": "2015-03-09",
      "last_synced_at": "2026-10-14T09:45:54.921Z",
      "location_count": 2,
      "location_summary": "Birmingham, Alabama • San Francisco, California",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00006441"
    },
    {
      "nct_id": "NCT01328041",
      "title": "A Study to Assess Dolutegravir in HIV-infected Subjects With Treatment Failure on an Integrase Inhibitor Containing Regimen.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Infection, Human Immunodeficiency Virus"
      ],
      "interventions": [
        {
          "name": "dolutegravir",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ViiV Healthcare",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 183,
      "start_date": "2011-05",
      "completion_date": "2015-05",
      "has_results": true,
      "last_update_posted_date": "2016-01-07",
      "last_synced_at": "2026-10-14T09:45:54.921Z",
      "location_count": 42,
      "location_summary": "Beverly Hills, California • Fountain Valley, California • Los Angeles, California + 32 more",
      "locations": [
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Fountain Valley",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01328041"
    }
  ]
}